As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
"We will look at the future more than the past. Daiichi has already sent its plans to the FDA, and we are waiting for a response from the regulators," Atul Sobti, the company's new CEO, said.